GPR55 is an orphan receptor whose endogenous agonists include lysophosphatidylinositol (LPI) and N‑acetylethanolamides (NAEs), such as palmitoylethanolamide (PEA) and anandamide. Furthermore, its physiology in the central nervous system involves motor coordination, procedural and spatial memory, pain, and anxiety, among others. Recent reports indicate that systemic injections of O‑1602 (a GPR55 and GPR18 agonist) blocked the reinforcing effects of morphine and nicotine in the conditioned place preference (CPP) paradigm, suggesting a possible participation of peripheral and/or central GPR55/GPR18 in brain reward/anti‑reward systems. In this pilot study, the endogenous GPR55 agonists LPI and PEA, the highly selective GPR55 synthetic agonist ML184 or the selective GPR55 antagonist ML193 were injected to examine their pharmacological effects on the reinforcing actions of nicotine in the CPP paradigm. Our preliminary study shows that injections of LPI, PEA, ML184 and ML193 interfered with the change in place preference induced by nicotine via mechanisms that remain to be identified (which probably include central GPR55).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.55782/ane-2022-029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-Inflammatory Effects of GPR55 Agonists and Antagonists in LPS-Treated BV2 Microglial Cells.
Pharmaceuticals (Basel)
May 2024
Neuroimmunology and Neurochemistry Research Group, Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, D-79104 Freiburg, Germany.
Chronic inflammation is driven by proinflammatory cytokines such as interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α), and chemokines, such as c-c motif chemokine ligand 2 (CCL2), CCL3, C-X-C motif chemokine ligand 2 (CXCL2), and CXCL10. Inflammatory processes of the central nervous system (CNS) play an important role in the pathogenesis of various neurological and psychiatric disorders like Alzheimer's disease, Parkinson's disease, and depression. Therefore, identifying novel anti-inflammatory drugs may be beneficial for treating disorders with a neuroinflammatory background.
View Article and Find Full Text PDFGPR55 activation improves anxiety- and depression-like behaviors of mice during methamphetamine withdrawal.
Heliyon
May 2024
Department of Forensic Science, School of Basic Medical Science, Xinjiang Medical University, Urumqi, 830011, China.
Methamphetamine is a potent and highly addictive neurotoxic psychostimulant that triggers a spectrum of adverse emotional responses during withdrawal. G-protein coupled receptor 55 (GPR55), a novel endocannabinoid receptor, is closely associated with mood regulation. Herein, we developed a murine model of methamphetamine-induced anxiety- and depressive-like behavior during abstinence which showed a decreased GPR55 expression in the hippocampus.
View Article and Find Full Text PDFHeteromers Formed by GPR55 and Either Cannabinoid CB or CB Receptors Are Upregulated in the Prefrontal Cortex of Multiple Sclerosis Patients.
Int J Mol Sci
April 2024
Department of Morphology and Cell Biology, University of Oviedo, 33006 Oviedo, Spain.
Article Synopsis
- Multiple sclerosis (MS) is a serious autoimmune and neurodegenerative disease affecting the central nervous system, with no cure available, highlighting the need for new treatment options.
- The endocannabinoid system (ECS) has a crucial role in brain functions, and recent studies have shown that cannabinoid receptor interactions (heteromers) are relevant in neurodegenerative diseases, but their specific role in MS remains unclear.
- New research identified cannabinoid receptor complexes (CBR-GPR55) in the prefrontal cortex, showing increased presence in MS patients, suggesting these receptor complexes could be potential targets for future MS therapies.
Lysophosphatidylcholines Enriched with and Palmitoleic Acid Regulate Insulin Secretion via GPR119 Receptor.
ACS Med Chem Lett
February 2024
Faculty of Biotechnology and Food Sciences, Institute of Molecular and Industrial Biotechnology, Lodz University of Technology, Stefanowskiego 2/22, 90-537 Lodz, Poland.
Among lipids, lysophosphatidylcholines (LPCs) with various fatty acyl chains have been identified as potential agonists of G protein-coupled receptors (GPCRs). Recently, targeting GPCRs has been switched to diabetes and obesity. Concomitantly, our last findings indicate the insulin secretagogue properties of and palmitoleic acid (16:1, n-7) resulting from GPCR activation, however, associated with different signaling pathways.
View Article and Find Full Text PDFGPR55 Inactivation Diminishes Splenic Responses and Improves Neurological Outcomes in the Mouse Ischemia/Reperfusion Stroke Model.
Cells
February 2024
Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
Although strokes are frequent and severe, treatment options are scarce. Plasminogen activators, the only FDA-approved agents for clot treatment (tissue plasminogen activators (tPAs)), are used in a limited patient group. Moreover, there are few approaches for handling the brain's inflammatory reactions to a stroke.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!